Would Remsima save KRW 64.5 billion every year?

A statistics has been unveiled that medical expenses of the Crohn’s disease in U.K., Italia and France will decrease KRW 419.6 billion down for 5 years if the Celltrion’sbiosimilar‘Remsima’launches. In this statistics, the assumption was that 25% of patients using the original pharmaceutical product of ‘Remicade’ and 50% of newly diagnosed patients will be treated by Remsima.

Pacing with the l...